Market Research Logo

Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2017. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry recorded a marginal increase in the number of number deals and a decrease in deal values in 2017 with 4,840 deals worth USD362 billion, as compared to 4,838 deals worth USD404.9 billion in 2016. The oncology market recoded 1,654 deals in 2017, as compared to 1,596 deals in 2016. North America recorded a decrease in the number of deals and deal values with 3,040 deals worth USD225.8 billion in 2017, as compared to 3,148 deals worth USD271.6 billion in 2016. Licensing agreements recorded a marginal increase in the receipt of upfront payments with USD4.4 billion in 2017, as compared to USD4.3 billion in 2016.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five years.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceutical & Healthcare, Global, Deals Summary
2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2017
2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2017 by Quarter
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2017
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2017
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2017
2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2017
2.5.1 Johnson & Johnson Acquires Actelion for USD30 Billion
2.5.2 Gilead Sciences Acquires Kite Pharma for USD11.9 Billion
2.5.3 AstraZeneca Enters into Agreement with Merck
2.5.4 INC Research and inVentiv Health Merge
2.5.5 Becton, Dickinson Raises USD10.5 Billion in Public Offering of Notes
2.5.6 Thermo Fisher Scientific Acquires 99% Stake in Patheon for USD7.2 Billion
2.5.7 Baotou Dongbao Bio Tech to Raise up to USD5.6 Billion in Private Placement of Shares
2.5.8 Anthem Raises USD5.5 Billion in Private Placement of Notes
2.5.9 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer
2.5.10 Pamplona Capital Management Acquires Parexel International for USD5 Billion
3 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, 2017
3.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2017 by Quarter
3.1.2 Top M&A Deals in 2017
3.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2017
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2017
3.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2017 by Quarter
3.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2017
3.2.3 Top IPOs in 2017
3.2.4 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2017
3.2.5 Top Secondary Offerings in 2017
3.2.6 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2017
3.2.7 Top PIPE Deals in 2017
3.2.8 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2017
3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2017
3.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2017 by Quarter
3.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2017
3.3.3 Top Public Debt Offerings in 2017
3.3.4 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2017
3.3.5 Top Private Debt Placements in 2017
3.3.6 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2017
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2017
3.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2017 by Quarter
3.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2017
3.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 2017
3.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2017
3.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2017
3.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 2017
3.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2017
3.4.8 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 2017
3.4.9 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2017
3.4.10 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2017
3.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2017
3.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2017 by Quarter
3.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2017
3.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 2017
3.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2017
3.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2017
3.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2017
3.5.7 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 2017
3.5.8 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2017
3.5.9 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2017
3.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2017
3.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2017 by Quarter
3.6.2 Top Private Equity Deals in 2017
3.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2017
3.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2017
3.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2017 by Quarter
3.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2017
3.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2017
3.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2017
3.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year
3.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2017
3.7.7 Top Venture Financing Deals in 2017
4 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market
4.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2017
4.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2017 by Quarter
4.1.2 Oncology - Deals of the Year
4.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2017
4.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2017 by Quarter
4.2.2 Central Nervous System - Deals of the Year
4.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2017
4.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2017 by Quarter
4.3.2 Infectious Disease - Deals of the Year
4.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2017
4.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2017 by Quarter
4.4.2 Immunology - Deals of the Year
4.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2017
4.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2017 by Quarter
4.5.2 Cardiovascular - Deals of the Year
4.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2017
4.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2017 by Quarter
4.6.2 Metabolic Disorders - Deals of the Year
4.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2017
4.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2017 by Quarter
4.7.2 Gastrointestinal - Deals of the Year
5 Pharmaceuticals & Healthcare, Deal Summary, By Geography
5.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2017
5.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2017 by Quarter
5.1.2 North America - Deals of the Year
5.2 Pharmaceuticals & Healthcare, European Region Deals, 2017
5.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2017 by Quarter
5.2.2 Europe - Deals of the Year
5.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2017
5.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2017 by Quarter
5.3.2 Asia-Pacific - Deals of the Year
5.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2017
5.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2017 by Quarter
5.4.2 Rest of the World - Deals of the Year
6 Pharmaceuticals & Healthcare, Global, Top Financial Advisors
6.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2017
6.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2017
7 Further Information
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclosure information
7.5 Disclaimer
1.1 List of Tables
Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 2017
Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2017
Table 5: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 7: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2017
Table 8: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2017
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 11: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 12 Pharmaceuticals & Healthcare, Global, Top IPOs, 2017
Table 13: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 14: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2017
Table 15: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 16: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2017
Table 17: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2017
Table 18: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 20: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 21: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2017
Table 22: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 23: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2017
Table 24: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2017
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2017
Table 28: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2017
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2017
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2017
Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2017
Table 32: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2017
Table 33: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2017
Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2017
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2017
Table 38: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2017
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2017
Table 40: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015 - Q4 2017
Table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2017
Table 42: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2017
Table 43: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2017
Table 44: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2017
Table 45: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 47: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2017
Table 48: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2017
Table 49: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2017
Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2017
Table 53: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2017
Table 54: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2017
Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2017
Table 56: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 58: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 60: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 62: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 64: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 66: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 68: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Table 70: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Table 72: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 73: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Table 74: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 75: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Table 76: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2013 - 2017
Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Table 78: Pharmaceuticals & Healthcare, Global,, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2017
Table 79: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2017
1.2 List of Figures
Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2013- 2017
Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Figure 3: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), 2017
Figure 4: Pharmaceuticals & Healthcare, Global, Deal Values (%), 2017
Figure 5 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 6 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 7: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2017
Figure 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 10: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 11: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 12: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 13: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2017
Figure 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 15: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 16: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 17: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 18: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2017
Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 20: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2017
Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2017
Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 2017
Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2017
Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2017
Figure 26: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2017
Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2017
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2017
Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2017
Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2017
Figure 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, 2017
Figure 34: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 2017
Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 2017
Figure 36: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 37: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 38: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2017
Figure 39: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 40: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 41: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2017
Figure 42: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2017
Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2017
Figure 44: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2017
Figure 45: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 46: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2017, 2013 - 2017
Figure 48: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 50: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Figure 51: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 52: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 53: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 54: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 55: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 56: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 57: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2013 - 2017
Figure 58: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2017-Q4 2017
Figure 59: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 60: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Figure 61: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 62: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Figure 63: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 64: Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Figure 65: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), 2013 - 2017
Figure 66: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), Q1 2017-Q4 2017
Figure 67: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2017
Figure 68: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report